<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39334467</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Pentraxin-3 (PTX-3) as a potential biomarker for predicting death in hospitalized patients with COVID-19.</ArticleTitle><Pagination><StartPage>233</StartPage><MedlinePgn>233</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02501-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pentraxin 3 (PTX3) is an acute-phase protein that belongs to the pentraxin family, which plays an important role in the body's defense against pathogens. PTX3 levels have been associated with inflammatory processes, and it is a possible biomarker for the diagnosis and prognosis of different infectious diseases, including COVID-19. The objective of this study was to analyze the potential of PTX3 as a plasma biomarker for predicting death in patients hospitalized with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study included a total of 312 patients with COVID-19, admitted from July 2020 to August 2021 to hospital ward and intensive care unit beds at two hospitals in the Northeast Region of Brazil. PTX3 was measured using ELISA in samples collected within 24 h after hospital admission. Maximally selected rank statistics were used to determine the PTX3 cutoff point that best distinguished patients who died from those who survived. A receiver operating characteristic (ROC) curve was used to determine the performance of the biomarker. Survival analysis was performed using a Kaplan-Meier curve, and a Cox regression model was used to determine predictors associated with death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 312 patients included in the study, 233 recovered and 79 died. Patients who died had higher PTX3 levels at the time of admission, when compared to those who recovered (median: 52.84 versus 10.79 ng/mL; p &lt; 0.001). PTX3 showed area under the ROC (AUC) = 0.834, higher than other markers used in clinical practice, such as C-reactive protein (AUC = 0.72) and D-dimer (AUC = 0.77). Furthermore, according to the Kaplan-Meier survival curve, patients with PTX3 concentrations above the cutoff point (27.3 ng/mL) had a lower survival rate (p = 0.014). In multivariate Cox regression, PTX3 &gt; 27.3 ng/mL was an important predictor of death, regardless of other confounding factors (hazard ratio = 1.79; p = 0.027).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PTX3 can be considered as a potential biomarker for predicting death in patients hospitalized with COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Milena Xavier Silva</ForeName><Initials>MXS</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Biosciences, Universidade Federal do Vale do São Francisco, Av. José de Sá Maniçoba. sn, Petrolina, Pernambuco, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa Armstrong</LastName><ForeName>Anderson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine, Universidade Federal do Vale do São Francisco (UNIVASF), Pernambuco, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Carlos Dornels Freire</ForeName><Initials>CDF</Initials><AffiliationInfo><Affiliation>College of Medicine, Universidade Federal do Vale do São Francisco (UNIVASF), Pernambuco, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>do Carmo</LastName><ForeName>Rodrigo Feliciano</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Biosciences, Universidade Federal do Vale do São Francisco, Av. José de Sá Maniçoba. sn, Petrolina, Pernambuco, Brazil. rodrigo.carmo@univasf.edu.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Universidade Federal do Vale do São Francisco (UNIVASF), Pernambuco, Brazil. rodrigo.carmo@univasf.edu.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IBPG-1896-4.03/21</GrantID><Agency>Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco</Agency><Country /></Grant><Grant><GrantID>APQ-0422-2.02/19</GrantID><Agency>Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco</Agency><Country /></Grant><Grant><GrantID>10/2021</GrantID><Agency>Health Secretariat of Pernambuco</Agency><Country /></Grant><Grant><GrantID>001</GrantID><Agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000683">Serum Amyloid P-Component</NameOfSubstance></Chemical><Chemical><RegistryNumber>148591-49-5</RegistryNumber><NameOfSubstance UI="C077657">PTX3 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="Y">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000683" MajorTopicYN="Y">Serum Amyloid P-Component</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="Y">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Innate immunity</Keyword><Keyword MajorTopicYN="N">Pentraxin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>RFC is Senior Editor at BMC Series.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334467</ArticleId><ArticleId IdType="pmc">PMC11428883</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02501-z</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02501-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO, World Health Organization. Who Director-General’s opening remarks at the media briefing on COVID-19- 11 march 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 Accessed May 31, 2024.</Citation></Reference><Reference><Citation>Worldometers. https://www.worldometers.info/coronavirus/ Accessed April 29, 2024.</Citation></Reference><Reference><Citation>Brazil P, Coronavirus. https://covid.saude.gov.br/ Accessed April 29, 2024.</Citation></Reference><Reference><Citation>Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly. Accessed May 31. 2024. https://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D, Latini R. (2019). Pentraxin 3 in cardiovascular disease. In Frontiers in Immunology (Vol. 10). Frontiers Media S.A. 10.3389/fimmu.2019.00823</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481278</ArticleId><ArticleId IdType="pubmed">31057548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Matzuk MM, Zhou XJ, Lu CY. Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury. Kidney Int. 2012;82(11):1195–207. 10.1038/ki.2012.268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499641</ArticleId><ArticleId IdType="pubmed">22895517</ArticleId></ArticleIdList></Reference><Reference><Citation>Assandri R, Monari M, Colombo A, Dossi A, Montanelli A. Pentraxin 3 plasma levels and Disease Activity in systemic Lupus Erythematosus. Autoimmune Dis. 2015;2015. 10.1155/2015/354014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646995</ArticleId><ArticleId IdType="pubmed">26613049</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrini E, Mantovani A, Garlanda C. The dual complexity of PTX3 in Health and Disease: a Balancing Act? Trends in Molecular Medicine. Volume 22. Elsevier Ltd; 2016. pp. 497–510. 10.1016/j.molmed.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5414840</ArticleId><ArticleId IdType="pubmed">27179743</ArticleId></ArticleIdList></Reference><Reference><Citation>Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, A HUMORAL PATTERN RECOGNITION MOLECULE, IN INNATE IMMUNITY, TISSUE REPAIR, AND CANCER. Physiol Rev. 2018;98:623–39. 10.1152/physrev.00016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985957</ArticleId><ArticleId IdType="pubmed">29412047</ArticleId></ArticleIdList></Reference><Reference><Citation>Assandri R, Accordino S, Canetta C, Buscarini E, Scartabellati A, Tolassi C, Serana F. Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives. Biochemia Med. 2022;32(2). 10.11613/BM.2022.020901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8996318</ArticleId><ArticleId IdType="pubmed">35464745</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetta E, Folci M, Bottazzi B, de Santis M, Gritti G, Protti A, Mapelli SN, Bonovas S, Piovani D, Leone R, My I, Zanon V, Spata G, Bacci M, Supino D, Carnevale S, Sironi M, Davoudian S, Peano C, Mantovani A. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2021;22(1):19–24. 10.1038/s41590-020-00832-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Capra AP, Crupi L, Pantò G, Repici A, Calapai F, Squeri R, Ardizzone A, Esposito E. Serum pentraxin 3 as Promising Biomarker for the long-lasting inflammatory response of COVID-19. Int J Mol Sci. 2023;24(18). 10.3390/ijms241814195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10531731</ArticleId><ArticleId IdType="pubmed">37762499</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, Bogaard HJ, Tuinman PR, van Agtmael MA, Hamann J, Teunissen CE, Wiersinga WJ, Koos) Zwinderman AH, Brouwer MC, van de Beek D, Vlaar APJ. (2021). Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine, 67. https://doi.org/10.1016/j.ebiom.2021.103378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118723</ArticleId><ArticleId IdType="pubmed">34000622</ArticleId></ArticleIdList></Reference><Reference><Citation>Feitosa TA, de Souza Sá MV, Pereira VC, de Andrade Cavalcante MK, Pereira VRA, da Costa Armstrong A, do Carmo RF. Association of polymorphisms in long pentraxin 3 and its plasma levels with COVID-19 severity. Clin Experimental Med. 2023;23(4):1225–33. 10.1007/s10238-022-00926-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619017</ArticleId><ArticleId IdType="pubmed">36315310</ArticleId></ArticleIdList></Reference><Reference><Citation>Genç AB, Yaylaci S, Dheır H, Genç AC, İşsever K, Çekiç D, Kocayığıt H, Çokluk E, Karacan A, Şekeroğlu MR, Çakar T, H., Güçlü E. The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia. Turk J Med Sci. 2021;51(2):448–53. 10.3906/sag-2011-32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219078</ArticleId><ArticleId IdType="pubmed">33315349</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutmann C, Takov K, Burnap SA, Singh B, Ali H, Theofilatos K, Reed E, Hasman M, Nabeebaccus A, Fish M, McPhail MJ, O’Gallagher K, Schmidt LE, Cassel C, Rienks M, Yin X, Auzinger G, Napoli S, Mujib SF, Mayr M. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun. 2021;12(1). 10.1038/s41467-021-23494-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184784</ArticleId><ArticleId IdType="pubmed">34099652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen CB, Sandholdt H, Møller MEE, Pérez-Alós L, Pedersen L, Bastrup Israelsen S, Garred P, Benfield T. Prediction of respiratory failure and mortality in COVID-19 patients using long Pentraxin PTX3. J Innate Immun. 2022. 10.1159/000521612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9059012</ArticleId><ArticleId IdType="pubmed">35066500</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JL, Bain W, Naqvi A, Staines B, Castanha PMS, Yang H, Boltz VF, Barratt-Boyes S, Marques ETA, Mitchell SL, Methe B, Olonisakin TF, Haidar G, Burke TW, Petzold E, Denny T, Woods CW, McVerry BJ, Lee JS, Mellors JW. Severe Acute Respiratory Syndrome Coronavirus 2 Viremia is Associated with Coronavirus Disease 2019 Severity and predicts clinical outcomes. Clin Infect Dis. 2022;74(9):1525–33. 10.1093/cid/ciab686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9070832</ArticleId><ArticleId IdType="pubmed">34374761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapadula G, Leone R, Bernasconi DP, Biondi A, Rossi E, D’Angiò M, Bottazzi B, Bettini LR, Beretta I, Garlanda C, Valsecchi MG, Mantovani A, Bonfanti P. Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Front Immunol. 2022;13. 10.3389/fimmu.2022.933960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651085</ArticleId><ArticleId IdType="pubmed">36389697</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulana Z, Bagherzadeh M, Mirzakhani M, Rostami A, Mohammadnia-Afrouzi M, Shahbazi M. Increased levels of serum Pentraxin 3 in critical coronavirus Disease-2019 patients. Environ Sci Pollut Res. 2022;29(57):85569–73. 10.1007/s11356-021-15183-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248285</ArticleId><ArticleId IdType="pubmed">34212320</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi A, Pesce F, Laterza R, D’Alise MG, Lovero R, Fontana A, Contino R, di Serio F. Pentraxin 3: potential prognostic role in SARS-CoV-2 patients admitted to the emergency department. Journal of infection. Volume 82. W.B. Saunders Ltd; 2021. pp. 84–123. 10.1016/j.jinf.2020.10.027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605789</ArticleId><ArticleId IdType="pubmed">33147434</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. (2022). Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. In Frontiers in Immunology (Vol. 13). Frontiers Media S.A. 10.3389/fimmu.2022.857573</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9091347</ArticleId><ArticleId IdType="pubmed">35572561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are Associated with Disease Severity and Mortality in patients with systemic inflammatory response syndrome. PLoS ONE. 2013;8(9). 10.1371/journal.pone.0073119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767672</ArticleId><ArticleId IdType="pubmed">24039869</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M, Xiong Y, Zhu C, Xu H, Zheng Q, Hu C, Jiang Y, Zou L, Xiao X, Chen F, Zhu Y. Elevated serum pentraxin-3 levels is positively correlated to disease severity and coagulopathy in covid-19 patients. Mediterranean J Hematol Infect Dis. 2021;13(1). 10.4084/MJHID.2021.015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813280</ArticleId><ArticleId IdType="pubmed">33489054</ArticleId></ArticleIdList></Reference><Reference><Citation>Porte R, Davoudian S, Asgari F, Parente R, Mantovani A, Garlanda C, Bottazzi B. (2019). The long pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis. In Frontiers in Immunology (Vol. 10, Issue APR). Frontiers Media S.A. 10.3389/fimmu.2019.00794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6473065</ArticleId><ArticleId IdType="pubmed">31031772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulicka-Grodzicka J, Surdacki A, Surmiak M, Sanak M, Wizner B, Sydor W, Bociąga-Jasik M, Strach M, Korkosz M, Skladany L, Grgurevic I, Podrug K, Kukla M. Chemerin as a potential marker of resolution of inflammation in COVID-19 infection. Biomedicines. 2022;10(10). 10.3390/biomedicines10102462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599036</ArticleId><ArticleId IdType="pubmed">36289725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>